Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 20/20 | 0.83 |
| ▸ | ECE1 | P42892 | 1/20 | 0.77 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27827907 | 1.00 | GLP1R (0.83) | GLP1RECE1MUS81 | |
| SCHEMBL29942457 | 1.00 | GLP1R (0.83) | GLP1RECE1MUS81 | |
| SCHEMBL29823404 | 1.00 | GLP1R (0.83) | GLP1RECE1MUS81 | |
| SCHEMBL31731011 | 1.00 | GLP1R (0.83) | GLP1RECE1MUS81 | |
| SCHEMBL29363146 | 1.00 | GLP1R (0.83) | GLP1RECE1MUS81 | |
| SCHEMBL30721588 | 1.00 | GLP1R (0.83) | GLP1RECE1MUS81 | |
| SCHEMBL29362765 | 1.00 | GLP1R (0.83) | GLP1RECE1MUS81 | |
| SCHEMBL30518507 | 1.00 | GLP1R (0.83) | GLP1RECE1MUS81 | |
| SCHEMBL30721547 | 0.99 | GLP1R (0.83) | GLP1R | |
| SCHEMBL31072729 | 0.99 | GLP1R (0.81) | GLP1RECE1MUS81 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 831 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130971-A1 | ACYLATED GLP-1 DERIVATIVE | SCIWIND BIOSCIENCES CO LTD (CN) | 2026-05-14 | — | — | US | claimed |
| US-12616739-B2 | GLP-1 prodrugs and uses thereof | NOVO NORDISK A/S (DK) | 2026-05-05 | — | — | US | claimed |
| EP-3452049-B1 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS INC (US) | 2026-04-01 | — | — | EP | claimed |
| US-12508300-B2 | Acylated GLP-1 derivative | SCIWIND BIOSCIENCES CO., LTD (CN) | 2025-12-30 | — | — | US | claimed |
| US-12435149-B2 | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists | AMGEN INC. (US) | 2025-10-07 | — | — | US | claimed |
| EP-3787631-B1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | UNIV EMORY (US) | 2025-09-10 | — | — | EP | claimed |
| US-20250276043-A1 | Pharmaceutical Composition Containing GLP-1 Compound | GAN & LEE PHARMACEUTICALS CO., LTD. (CN) | 2025-09-04 | — | — | US | claimed |
| US-20250276068-A1 | PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USES THEREOF | BEIJING QL BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-09-04 | — | — | US | claimed |
| WO-2025133045-A1 | FERMENTATION PROCESS | NOVO NORDISK A/S (DK) | 2025-06-26 | — | — | WO | claimed |
| WO-2025128968-A1 | AZA GLP-1-BASED THERAPEUTIC ANALOGUES | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2025-06-19 | — | — | WO | claimed |
| CN-114621339-A | Long-acting GLP-1 derivative | 北京惠之衡生物科技有限公司 | 2022-06-14 | — | — | CN | claimed |
| CN-114621340-A | Acylated long-acting GLP-1 derivative | 北京惠之衡生物科技有限公司 | 2022-06-14 | — | — | CN | claimed |
| CN-113621046-B | Use and method of polymer anion exchange filler in preparation of liraglutide | 重庆宸安生物制药有限公司 | 2022-05-27 | — | — | CN | claimed |
| EP-3236937-B1 | CONTROLLED-RELEASE FORMULATIONS | CAMURUS AB (SE) | 2022-05-04 | — | — | EP | claimed |
| EP-2637698-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2022-04-20 | — | — | EP | claimed |
| CN-112522294-B | Semi-recombinant preparation method of GLP-1 analogue | 珠海冀百康生物科技有限公司 | 2022-03-22 | — | — | CN | claimed |
| CN-107412742-B | Pharmaceutical composition comprising a GLP-1 peptide or exendin-4 peptide and a basal insulin peptide | 诺沃—诺迪斯克有限公司 | 2022-03-15 | — | — | CN | claimed |
| US-20220062184-A1 | Pharmaceutical Composition for Oral GLP-1 Administration Comprising a Tablet Core and Immediate Release Coating | NOVO NORDISK AS (DK) | 2022-03-03 | — | — | US | claimed |
| CN-107108714-B | GLP-1 derivatives and uses thereof | 诺和诺德股份有限公司 | 2022-02-08 | — | — | CN | claimed |
| CN-106999602-B | GLP-1 derivatives and uses thereof | 诺和诺德股份有限公司 | 2022-02-01 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12508300-B2 | Acylated GLP-1 derivative | GLP1R, GIPR, VIP | GLP1R 1/4885ECE1 3559/4885MUS81 4877/4885 |
| US-20260130971-A1 | ACYLATED GLP-1 DERIVATIVE | GLP1R, NPY1R, NPY4R | GLP1R 1/4885ECE1 3502/4885MUS81 4770/4885 |
| US-20250276068-A1 | PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USES THEREOF | GLP1R, GIPR, IAPP | GLP1R 1/4885ECE1 1562/4885MUS81 4605/4885 |
| US-12616739-B2 | GLP-1 prodrugs and uses thereof | GLP1R, SLC5A1, IAPP | GLP1R 1/4885ECE1 542/4885MUS81 3970/4885 |
| US-20220062184-A1 | Pharmaceutical Composition for Oral GLP-1 Administration Comprising a Tablet Core and Immediate Release Coating | GLP1R, GIPR, IAPP | GLP1R 1/4885ECE1 1324/4885MUS81 4833/4885 |
| US-20250276043-A1 | Pharmaceutical Composition Containing GLP-1 Compound | GLP1R, GIPR, SLC5A1 | GLP1R 1/4885ECE1 2544/4885MUS81 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.